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Abstract
Background: The International Consensus Guidelines (ICG) stratify risk for malignancy in patients with
intraductal papillary mucinous neoplasm (IPMN) into three progressive categories according to whether
patients show ‘no criteria’, ‘worrisome features’ (WFs) or ‘high-risk stigmata’ (HRS).
Objectives: This study was conducted to test the hypothesis that type (clinical versus radiological) and
quantity of ICG WFs and HRS carry unequal weight and are not cumulative in the prediction of risk for
malignancy or invasiveness in IPMN.
Methods: A retrospective review of a prospectively maintained database of patients who underwent
surgical resection for IPMN at a single, university-based medical centre during 1992–2012 was per-
formed. Differences that achieved a P-value of <0.05 were considered significant.
Results: Of 362 patients, 340 were eligible for entry into the study and were categorized as demon-
strating no criteria (n = 70), WFs (n = 185) or HRS (n = 85). Patients in the WFs group had higher rates of
malignant and invasive IPMN than those in the no-criteria group [26.5% versus 4.3% (P < 0.0001) and
15.7% versus 4.3% (P = 0.02), respectively]. Patients in the HRS group had higher rates of malignant and
invasive IPMN than those in the WFs group [56.5% versus 26.5% (P = 0.0001) and 42.4% versus 15.7%
(P = 0.0001), respectively]. When radiological parameters only were considered for WFs versus HRS, no
difference was found in rates of malignant or invasive IPMN. By contrast, when clinical parameters only
were considered, patients in the HRS group had higher rates of malignant or invasive IPMN [66.7% versus
8.1% (P = 0.04) and 66.7% versus 2.7% (P = 0.01), respectively]. There was no stepwise increase in rates
of malignant or invasive IPMN with the number of WFs. However, patients with only one WF had a lower
risk for malignancy than patients with two or more WFs.
Conclusions: The type and quantity of ICG WFs and HRS carry unequal weight and are not cumulative
in the prediction of risk for malignancy or invasiveness in IPMN.
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Introduction
Intraductal papillary mucinous neoplasm (IPMN) was first
described by Ohashi et al. in 19821 in a series of four mucinous
neoplasms of the pancreas with pancreatic ductal ectasia. It was
then considered an unusual pancreatic entity. Today, it is believed
to account for up to 70% of all cystic neoplasms of the pancreas
and is the lead indication for pancreatic resection for pancreatic
cystic tumours (10–20% of all pancreatectomies).2 The reasons
for the ‘IPMN epidemic’ are unknown, but it is likely to reflect
increased awareness and better detection with improved imaging
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resolution. Because of its increased recognition, the World Health
Organization (WHO) established criteria in 1996 to classify and
distinguish IPMN from other mucin-producing cystic neo-
plasms.3 Similarly, physicians, especially surgeons, felt the urge to
gather and discuss the management of this rather new entity. In
2006, the working group of the International Association of
Pancreatology proposed international consensus guidelines on
IPMN (Sendai Consensus Guidelines),4 which were revised and
updated in 2012.5
The precancerous nature of IPMN is now widely accepted to
imply a sequence of progression to malignancy from low-grade to
high-grade dysplasia and finally to invasive carcinoma (compa-
rable with the progression to malignancy of colonic polyps).6,7
The current International Consensus Guidelines5 established sur-
gical indications for IPMN based on several surgical series in
which rates and predictors of malignancy were analysed according
to IPMN histological subtype.With a risk for malignant transfor-
mation of 40–95%,8,9 it is recommended that all main duct (MD)
IPMN in fit patients are resected. Conversely, with an overall risk
for malignant transformation estimated at 6–40%,9–11 the close
surveillance of branch duct (BD) IPMN seems reasonable except if
select criteria are present or appear during follow-up. The Sendai
criteria for the management of BD-IPMN4 were replaced in 2012
by three categories of risk for malignancy according to which
patients are stratified as showing ‘no criteria’, ‘worrisome features’
(WFs) or ‘high-risk stigmata’ (HRS).5 A previous study published
by Ohtsuka et al. in 201212 analysed the Sendai criteria and con-
cluded that an increase in the number of predictive factors aug-
mented the sensitivity for predicting the malignant potential of
BD-IPMN. Similarly, the current International Consensus Guide-
lines,5 with their three categories of factors, seem to imply that
there is a linear relationship between the category and risk for
malignancy.
The present authors hypothesized that the type (clinical versus
radiological) and quantity of the 2012 International Consensus
Guidelines WFs and HRS are of unequal weight and are not
cumulative in the prediction of risk for malignancy or
invasiveness in IPMN.
Materials and methods
Patient selection
From 1992 to 2012, data for all patients who underwent surgical
pancreatic resection for IPMN at Indiana University Hospital
were prospectively collected in a database. For the purpose of this
study, this database was retrospectively analysed and sup-
plemented with a review of electronic medical records.
Data were compiled and reported in strict compliance with
patient confidentiality guidelines as defined by the Indiana Uni-
versity Institutional Review Board.
Parameters assessed
Based on the 2012 International Consensus Guidelines,5 a total of
nine preoperative parameters were assessed and categorized as
representing ‘no criteria’, ‘worrisome features’ or ‘high-risk stig-
mata’. The two clinical factors were a history of acute pancreatitis
and jaundice. Acute pancreatitis was defined according to the
Atlanta consensus or its 2012 revision.13 Acute pancreatitis was
diagnosed if two of the following three features were present:
abdominal pain consistent with acute pancreatitis; serum lipase
activity (or amylase activity) at least three times greater than the
upper limit of normal, and characteristic findings of acute pan-
creatitis on cross-sectional imaging studies.
The seven remaining factors were radiological and were evalu-
ated on preoperative cross-sectional imaging studies (computed
tomography or magnetic resonance imaging/magnetic resonance
cholangiopancreatography). They included the size of the largest
cyst (<3 cm or ≥3 cm) in BD-IPMN andmixed-type (MT) IPMN,
the diameter of the main pancreatic duct (<5 mm, 5–9 mm,
≥10 mm), the presence or absence of an enhancing solid compo-
nent within the cyst, a non-enhancing mural nodule, thickening
enhancing cyst walls or an abrupt change in the calibre of the
pancreatic duct with distal pancreatic atrophy and lymphad-
enopathy.
Pathology
The presence of malignancy as defined by theWHO14 (high-grade
dysplasia, formerly carcinoma in situ and invasive carcinoma) and
the degree of dysplasia in non-malignant lesions (low-grade and
moderate-grade dysplasia) were assessed on final pathology of the
surgical specimen. All pathological specimens were reviewed by
staff pathologists to confirm the diagnosis of IPMN. Histology
was consistent with IPMN if it showed an intraductal prolifera-
tion of tall, columnar, mucin-producing cells, arising from the
main pancreatic duct and/or a branch duct, with or without
papillary projections, and without ovarian-type stroma.
Intraductal papillary mucinous neoplasms were also classified
into BD-IPMN, MD-IPMN or MT-IPMN based on gross and
microscopic histological findings.5,15,16 For the purpose of the
present study, mixed-type variants were considered as MD-IPMN
because of the main pancreatic duct involvement.
Exclusion criteria
Patients for whom pathological data were incomplete or whose
final pathological diagnosis was not consistent with IPMN were
excluded from this study. Patients were also excluded if documen-
tation for all the features described in the 2012 International
Consensus Guidelines was not available.
Statistical analysis
Data were recorded using Microsoft Excel 2011 (Microsoft, Inc.,
Redmond,WA, USA) and analysed with GraphPad Prism Version
5.0 (GraphPad Software, Inc., La Jolla, CA, USA). Descriptive
statistics of continuous data included the mean, median, standard
error (SE), range and percentage. For subgroup comparisons on
categorical data, proportions were compared with Fisher’s exact
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test as appropriate. Student’s t-test was used to compare continu-
ous variables. A P-value of < 0.05 was accepted as indicating
statistical significance.
Results
Patient population
Between 1992 and 2012, 362 patients were diagnosed with IPMN
and subsequently underwent surgical resection. Complete data
were available for 340 patients, who were included in this study.
Their mean ± SE age was 68.2 ± 11.6 years (range: 31–93 years)
and the gender ratio of the sample was 0.94 (165 men and 175
women).
International Consensus Guidelines parameters
Based on the 2012 International Consensus Guidelines, ‘worri-
some features’ (WFs) included a history of acute pancreatitis, a
cyst size of ≥3 cm, a main pancreatic duct diameter of 5–9 mm, a
non-enhancing mural nodule and lymphadenopathy. ‘High-risk
stigmata’ (HRS) included jaundice, the presence of an enhancing
solid component within the cyst or a main pancreatic duct diam-
eter of ≥10 mm. In the present population, 70 patients (20.6%)
were diagnosed as showing ‘no criteria’, 185 (54.4%) withWFs and
85 (25.0%) with HRS.
Contrary to the Sendai criteria, which described predictors of
malignancy for BD-IPMN only, the 2012 International Consensus
Guidelines algorithm analyses IPMNs altogether, considering
main duct dilation as aWF or HRS (depending on the diameter of
the main duct). Therefore, the present authors decided to analyse
both BD-IPMN and MD/MT-IPMN together in the way pre-
sented in the revised guidelines. The analysis of MD/MT-IPMN
alone raised the issue of bias as main duct dilation itself already
represents a WF or HRS; hence, in order to achieve a thorough
analysis, BD-IPMN was also analysed separately.
Pathology
Pathology was consistent with BD-IPMN and MD-IPMN (or
MT-IPMN) in 170 patients (50.0%) and 170 patients (50.0%),
respectively. On pathology review, 100 IPMNs (29.4%) were clas-
sified as malignant, 32 (9.4%) as high-grade dysplasia and 68
(20.0%) as invasive carcinoma. The remaining 240 benign IPMNs
(70.6%) included 152 low-grade dysplasia IPMN (44.7%) and 88
moderate-grade dysplasia IPMN (25.9%).
Progression in risk for malignancy or invasiveness
across the three categories
There was a significant increase in the rates of malignant and
invasive IPMN with the category of factors, as shown in Fig. 1.
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Figure 1 Risk for malignancy and invasiveness in intraductal papillary mucinous neoplasm (IPMN) according to the categories in the 2012
International Consensus Guidelines. All P-values are significant at < 0.05
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Patients with no criteria, with WFs and with HRS had risks for
malignancy of 4.3%, 26.5% and 56.5%, respectively. Similarly,
rates of invasive IPMN were 4.3%, 15.7% and 42.4%, respectively,
in the same three categories.
Importance of each factor for the prediction of risk
for malignancy or invasiveness
A total of 97 (52.4%) of the 185 patients with WFs had radiologi-
cal WFs. Thirty (35.3%) of the 85 patients with HRS had radio-
logical HRS. However, 37 (20.0%) of theWFs patients had clinical
WFs and three (3.5%) of the HRS patients had clinical HRS.
When radiological parameters only were considered, no difference
in rates of malignant or invasive IPMN was found between
patients with WFs and HRS, respectively. By contrast, when only
clinical factors were taken into account, patients with HRS had
higher rates of malignant and invasive lesions (8.1% versus 66.7%
and 2.7% versus 66.7%; P = 0.036 and P = 0.011, respectively).
These results are summarized in Table 1.
Influence of the number of factors on the prediction
of risk for malignancy or invasiveness
Of the 185 patients with WFs, 104 (56.2%) patients had one WF,
70 (37.8%) had two WFs and 11 (5.9%) had three or more WFs.
Of the 85 patients with HRS, 80 (94.1%) had one HRS and five
(5.9%) had two. A comparison of risk for malignancy and
invasiveness in patients with one versus two, two versus three and,
finally, one versus three WFs is displayed in Table 2. The only
statistically significant difference was found for malignant IPMN
and pertained to the difference between patients with one or two
WFs, respectively. To further analyse this association, patients with
only oneWF were compared with patients with two or moreWFs.
Patients with only oneWFwere found to have a significantly lower
rate of malignant IPMN (15.4% versus 40.7%; P = 0.0002), sug-
gesting an additive risk when two or more WFs were present.
When only radiological factors were considered (Table 3), similar
overall results became apparent and a similar additive risk in
patients with two or more radiological WFs emerged (19.4%
versus 58.6%; P = 0.0006).
When patients with one HRS were compared with patients with
two or more, a trend toward greater rates of malignant and inva-
sive IPMN emerged with more HRS, although it did not reach
statistical significance [malignancy: 53.8% versus 100% (P =
0.065); invasiveness: 40.0% versus 80.0% (P = 0.16)].
Influence of the association of HRS and WFs
The presence of at least one HRS causes a patient to fall into the
HRS category, regardless of the presence of WFs. However, an
analysis to establish whether the association of WFs and HRS was
cumulative was conducted. Among the 85 patients in the HRS
category, 15 (17.6%) had HRS only, whereas 70 (82.4%) had both
WFs and HRS. Interestingly, the presence of HRS only was asso-
ciated with higher rates of malignant (86.7% versus 50.0%;
P = 0.01) and invasive IPMN (93.3% versus 34.3%; P = 0.0007).
Separate analysis of BD-IPMN
Similar results were found for BD-IPMN alone. There was a
stepwise increase in risk for malignancy and invasiveness across
patients with no criteria, WFs and HRS [5.3%, 12.2% and 43.5%,
respectively (P < 0.0001) for malignancy; 5.3%, 6.7% and 34.8%,
respectively (P = 0.0015) for invasiveness]. There was no difference
in risk for malignancy and invasiveness between radiological WFs
and radiological HRS. Conversely, clinical HRS were associated
with a greater rate of malignant IPMN than clinical WFs (100%
versus 4%; P = 0.008). There was no stepwise increase in rates of
malignant or invasive IPMN with the number of WFs. However,
patients with only one WF had a lower risk for malignancy than
patients with two or more WFs (6.9% versus 21.9%; P = 0.048).
Discussion
The 2012 International Consensus Guidelines5 classify patients
into three categories of risk based on several features that are
associated with malignancy and invasiveness. The present study
analysed the influence of the subtype and numbers of those
factors on the prediction of risk for malignancy and invasiveness
in IPMN. According to the present results, the type and quantity
of WFs and HRS carry unequal weight. Clinical parameters, in
general, are more predictive and should carry more weight in
surgical decision making. ‘Worrisome features’ and especially
radiological WFs are not cumulative in risk prediction as there is
no stepwise increase in rates of malignant or invasive IPMN with
the number of WFs. However, patients with only one WF should
be considered at lower risk for malignancy than patients with two
or moreWFs. Finally, the addition of WFs to HRS did not increase
rates of malignant or invasive IPMN in comparison with HRS
alone.
Invasive IPMN has a better prognosis than classic pancreatic
adenocarcinoma in patients matched by T1 or N0 status, or by the
subtype of colloid carcinoma. However, in the other conditions
(T2–T4, N1 and other pathological subtypes), invasive IPMN is
associated with a poor prognosis similar to that of classic pancre-
atic adenocarcinoma,17,18 with 5-year survival of 4–6%.19 Because
of this potential for malignancy, IPMNs have been resected in all
Table 1 Importance of the subtypes of ‘worrisome features’ (WFs)
and ‘high-risk stigmata’ (HRS) to the prediction of risk for malig-
nancy and invasiveness in intraductal papillary mucinous neoplasms
Criteria subtype Malignancy P-value Invasiveness P-value
Radiological WFs
(n = 97)
30 (30.9%) 0.66 20 (20.6%) 1
Radiological HRS
(n = 30)
11 (36.7%) 6 (20%)
Clinical WFs (n = 37) 3 (8.1%) 0.036a 1 (2.7%) 0.011a
Clinical HRS (n = 3) 2 (66.7%) 2 (66.7%)
aSignificant P-value (P < 0.05).
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patients for decades. As a result of the increased incidental detec-
tion of lesions in cross-sectional imaging studies20 and the benign
pathology of the majority of resected IPMNs, this approach has
had to change.21,22 In 2006, the International Association of
Pancreatology proposed guidelines for the management of IPMN
(the Sendai criteria).4 These first guidelines proved to be highly
sensitive (80–97%) but non-specific (25–30%) and to have a low
positive predictive value (14–22%),23–25 which led to the subopti-
mal detection of malignant IPMN and the over-treatment of
minimally or asymptomatic patients with non-malignant disease.
Subsequently, the guidelines were revisited and updated in 2012.
The new 2012 International Consensus Guidelines5 have since
been widely adopted in the surgical decision-making process.
The current study is subject to several limitations that must be
discussed here. It is a retrospective study covering over 20 years
spanning several periods of IPMN management based on differ-
ent protocols at this institution (according to indications for sur-
gical resection based on the presence of IPMN before 2000, the
Sendai criteria after 2006, and the 2012 guidelines more recently).
The present sample represents a surgical series and thus it
cannot be concluded whether these results can be generalized to a
surveillance population. In view of this selection bias, it was
decided that the study should include only patients who had been
operated on in order to ensure a confirmed diagnosis of IPMN
and of malignancy or invasiveness according to the final pathol-
ogy of the resected specimen, which represents the reference
standard for diagnosis. A mixed series (both surveillance and
surgery) would have shown the true incidence of WFs and HRS in
patients with IPMN, but would have been less than optimal in
assessing the true risks for malignancy and invasiveness. If
assessed on cross-sectional imaging, signs of malignancy (vascular
encasement, metastases, peritoneal carcinomatosis) imply late-
stage disease. The assessment of malignancy on cytopathology
also presents several drawbacks as the positive predictive value of
this method is excellent (near 100%), but the absence of
high-grade atypical cells or degenerated cells does not exclude the
possibility of malignancy.
To the present authors’ knowledge, to date no study has ana-
lysed the roles of both the number and type of criteria used in the
prediction of risk for malignancy. Only one study has analysed the
impact of the number of criteria. Despite being published in 2012,
a series by Ohtsuka et al.12 analysed the Sendai criteria and con-
cluded that an increase in the number of predictive factors aug-
mented the sensitivity of predictions of the malignant potential of
BD-IPMN. Since the International Consensus Guidelines were
updated, multiple studies have validated the impacts of HRS and
WFs in IPMN risk prediction. A recent meta-analysis of 5788
patients suggested that the contributions of those criteria to the
progression of IPMN to malignancy were unequal based on dif-
ferential odds ratios (ORs).26 In this meta-analysis, cyst size was
associated with the highest OR of 62, whereas mural nodule and
main duct involvement generated ORs of 9 and 7, respectively.26
Conversely, a recent German study concluded that even small
IPMNs without criteria suspicious for progression demonstrated
a rate of malignancy of 24.6%.27 Based on their controversial
results, this latter team advocate a more liberal policy in IPMN,
even in lesions that do not meet the guidelines criteria. However,
this study also based its analysis on the Sendai criteria rather than
on the updated WFs and HRS.27
These guidelines are based on results from large series and
general populations and may not be applicable on an individual-
patient basis. However, predicting the risk for malignancy or
invasiveness in each patient is more important as a patient with a
suspicious lesion will undergo standard oncological pancreatec-
tomy with lymphadenectomy, whereas a patient with supposedly
benign lesion(s) can undergo organ-sparing pancreatectomy or
even close surveillance. This decision presents several conse-
quences. Firstly, despite recent progress in pancreatic surgery, pan-
creatic resection is still associated with mortality rates of up to 5%
and morbidity rates of 20–40%.28,29 Secondly, a cost-effectiveness
Table 2 Influence of the number of ‘worrisome features’ (WFs) on the prediction of risk for malignancy and invasiveness in intraductal
papillary mucinous neoplasms (IPMN)
Number of WFs Malignant IPMN P-value Invasive IPMN P-value
1 (n = 104) 16 (15.4%)
<0.0002
a
0.098 11 (10.6%)
0.054
0.13
2 (n = 70) 29 (41.4%) 15 (21.4%)
≥3 (n = 11) 4 (36.4%) 1 3 (27.2%) 0.70
aSignificant P-value (P < 0.05).
Table 3 Influence of the number of radiological ‘worrisome features’ (WFs) on the prediction of risk for malignancy and invasiveness in
intraductal papillary mucinous neoplasms (IPMN)
Number of radiological WFs Malignant IPMN P-value Invasive IPMN P-value
1 (n = 67) 13 (19.4%)
<0.0005
a
0.37 10 (14.9%)
0.089
0.29
2 (n = 28) 16 (57.1%) 9 (32.1%)
≥3 (n = 2) 1 (50.0%) 1 1 (50.0%) 1
aSignificant P-value (P < 0.05).
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analysis published in 201030 concluded that surgery was associated
with a global incremental cost of more than US$20 000 dollars
over a surveillance strategy, which represents an increased
expense that is not justified in benign lesions. Based on those
limitations, the Memorial Sloan – Kettering Cancer Center
attempted to develop a preoperative nomogram in which clinical
and radiological criteria were combined into one system.31 On
the basis of this latter study and the present results, it would
appear that a malignancy score may be more accurate than stand-
ard risk categories as it will reflect the number and weight of each
feature.
The preoperative prediction of malignancy and invasiveness in
IPMN has been widely studied and has been summarized in the
2012 International Consensus Guidelines,5 which represent an
improvement on the 2006 Sendai criteria.4 However, the new algo-
rithm remains suboptimal in predicting risk for malignancy and
in maintaining a balance between under- and over-treatment
because it considers every parameter to have an equal association
with risk for malignancy, which the present study has proved to be
incorrect. A scoring system based on a large series and including
multivariate analysis and the calculation of ORs may prove more
adequate to accurately assess risk for malignancy or invasiveness
in IPMN.
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